Charles Schwab
PCVX icon

Charles Schwab’s Vaxcyte PCVX Stock Holding History

Charles Schwab’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.1M Buy
1,464,812
+60,864
+4% +$3.31M 0.01% 883
2026
Q1 		$81.6M Buy
1,403,948
+110,118
+9% +$5.98M 0.01% 840
2025
Q4 		$59.7M Buy
1,293,830
+423
+0% +$18.9K 0.01% 1039
2025
Q3 		$46.6M Sell
1,293,407
-124,304
-9% -$4.12M 0.01% 1200
2025
Q2 		$46.1M Buy
1,417,711
+84,329
+6% +$2.76M 0.01% 1155
2025
Q1 		$50.3M Sell
1,333,382
-8,391
-0.6% -$671K 0.01% 1064
2024
Q4 		$110M Buy
1,341,773
+45,936
+4% +$4.56M 0.02% 611
2024
Q3 		$148M Buy
1,295,837
+419,600
+48% +$37.8M 0.03% 470
2024
Q2 		$66.2M Buy
876,237
+42,619
+5% +$2.9M 0.01% 863
2024
Q1 		$56.9M Buy
833,618
+103,180
+14% +$7.14M 0.01% 944
2023
Q4 		$45.9M Buy
730,438
+17,570
+2% +$913K 0.01% 1035
2023
Q3 		$36.3M Buy
712,868
+104,398
+17% +$5.15M 0.01% 1112
2023
Q2 		$30.4M Buy
608,470
+120,837
+25% +$5.73M 0.01% 1203
2023
Q1 		$18.3M Sell
487,633
-846
-0.2% -$35.9K 0.01% 1542
2022
Q4 		$23.4M Buy
488,479
+143,253
+41% +$5.62M 0.01% 1327
2022
Q3 		$8.29M Buy
345,226
+55,579
+19% +$1.41M ﹤0.01% 1948
2022
Q2 		$6.3M Buy
289,647
+27,356
+10% +$633K ﹤0.01% 2086
2022
Q1 		$6.33M Buy
262,291
+19,972
+8% +$436K ﹤0.01% 2168
2021
Q4 		$5.76M Buy
242,319
+4,571
+2% +$106K ﹤0.01% 2279
2021
Q3 		$6.03M Buy
237,748
+65,145
+38% +$1.58M ﹤0.01% 2283
2021
Q2 		$3.89M Buy
172,603
+36,425
+27% +$746K ﹤0.01% 2471
2021
Q1 		$2.69M Buy
136,178
+18,585
+16% +$468K ﹤0.01% 2575
2020
Q4 		$3.13M Buy
117,593
+1,528
+1% +$56.8K ﹤0.01% 2450
2020
Q3 		$5.73M Buy
+116,065
New +$4.62M ﹤0.01% 1998

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Charles Schwab's PCVX Position: Q2 2026 in Review

Charles Schwab increased its Vaxcyte (PCVX) stake by 4.3% in Q2 2026, buying an estimated $3.31M and bringing the position to 1,464,812 shares worth $85.1M. The position accounts for 0.01% of the portfolio, ranked #883.

Charles Schwab first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $148M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Charles Schwab held 1,464,812 shares of Vaxcyte worth $85.1M as of Q2 2026.
  • Charles Schwab bought 60,864 Vaxcyte shares in Q2 2026, an estimated $3.31M.
  • Vaxcyte made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #883 holding.
  • Charles Schwab first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Charles Schwab's Vaxcyte position peaked at $148M in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.